Pharmacokinetic interactions between drugs and botanical dietary supplements

Drug Metabolism and Disposition

Volumn 44, Issue 2, 2016, Pages 162-171

  Sprouse, Alyssa A ^a   Van Breemen, Richard B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZPHETAMINE; BIOFLAVONOID; CAFFEINE; CONTRACEPTIVE AGENT; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DIAZEPAM; DICLOFENAC; GARLIC OIL; HYPERFORIN; ISOFLAVONE DERIVATIVE; KAVA; NATURAL PRODUCT; PARACETAMOL; SILIBININ; SILYMARIN; SITOSTEROL; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; DRUG; PLANT EXTRACT;

ACTAEA RACEMOSA; ANGELICA SINENSIS; BILBERRY; BINDING COMPETITION; CAMELLIA SINENSIS; CRANBERRY; CURCUMA LONGA; DANDELION; DIET SUPPLEMENTATION; DRUG BOTANICAL DIETARY SUPPLEMENT INTERACTION; DRUG EFFECT; DRUG INTERACTION; DRUG SAFETY; DRUG TRANSPORT; ECHINACEA PURPUREA; ENZYME INDUCTION; GARLIC; GINKGO BILOBA; GINSENG; GLYCYRRHIZA GLABRA; GLYCYRRHIZA URALENSIS; GRAPE; HUMAN; HUMULUS LUPULUS; HYDRASTIS; HYPERICUM PERFORATUM; MEDICINAL PLANT; OENOTHERA BIENNIS; PIPER METHYSTICUM; PRIORITY JOURNAL; RED CLOVER; REVIEW; SABAL; SILYBUM MARIANUM; SOYBEAN; TANACETUM PARTHENIUM; VALERIANA OFFICINALIS; XENOBIOTIC METABOLISM; ADVERSE EFFECTS; CLINICAL TRIAL (TOPIC); DIETARY SUPPLEMENT; HERB DRUG INTERACTION; HYPERICUM; METABOLISM; PRECLINICAL STUDY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; DRUG EVALUATION, PRECLINICAL; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; MILK THISTLE; PHARMACEUTICAL PREPARATIONS; PLANT EXTRACTS;

EID: 84958157318     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.066902     Document Type: Review

References (97)

1. Anderson GD, Rosito G, Mohustsy MA, and Elmer GW (2003) Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol 43:643-648.
2. Appiah-Opong R, Commandeur JNM, van Vugt-Lussenburg B, and Vermeulen NPE (2007) Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology 235:83-91.
3. Barnes PM, Bloom B, and Nahin RL (2008) Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 12:1-23.
4. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Böcker RH, Beckurts KT, Lang W, Hunz M, and Fuhr U (2000) Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 86:250-256.
5. Blendon RJ, Benson JM, Botta MD, and Weldon KJ (2013) Users' views of dietary supplements. JAMA Intern Med 173:74-76.
6. Blumenthal M, Lindstrom A, Ooyen C, and Lynch ME (2012) Herb supplement sales increase 4.5% in 2011. HerbalGram 95:60-64.
7. Brantley SJ, Argikar AA, Lin YS, Nagar S, and Paine MF (2014) Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos 42:301-317.
8. Brantley SJ, Graf TN, Oberlies NH, and Paine MF (2013) A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. Drug Metab Dispos 41:1662-1670.
9. Brauch H, Mürdter TE, Eichelbaum M, and Schwab M (2009) Pharmacogenomics of tamoxifen therapy. Clin Chem 55:1770-1782.
10. Budzinski JW, Foster BC, Vandenhoek S, and Arnason JT (2000) An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7:273-282.
11. Budzinski JW, Trudeau VL, Drouin CE, Panahi M, Arnason JT, and Foster BC (2007) Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. Can J Physiol Pharmacol 85:966-978.
12. Chatterjee P and Franklin MR (2003) Human cytochrome p450 inhibition and metabolicintermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 31:1391-1397.
13. Chen Y, Liu L, Monshouwer M, and Fretland AJ (2011) Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drugdrug interactions. Drug Metab Dispos 39:2085-2092.
14. Chow HHS, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, Xu MJ, Hsu CH, Ranger-Moore J, and Alberts DS (2006) Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 15:2473-2476.
15. Cohen PA (2012) Assessing supplement safety-the FDA's controversial proposal. N Engl J Med 366:389-391.
16. Cohen PA (2014) Hazards of hindsight-monitoring the safety of nutritional supplements. N Engl J Med 370:1277-1280.
17. Donovan JL, DeVane CL, Chavin KD, Wang JS, Gibson BB, Gefroh HA, and Markowitz JS (2004) Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 32:1333-1336.
18. Espié P, Tytgat D, Sargentini-Maier ML, Poggesi I, and Watelet JB (2009) Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 41:391-407.
19. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, and Choudri S (2001) An in vitro evaluation of human cytochrome P450 3A4 and Pglycoprotein inhibition by garlic. J Pharm Pharm Sci 4:176-184.
20. Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, and Arnason JT (2003) In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 10:334-342.
21. Foster BC, Vandenhoek S, Tang R, Budzinski JW, Krantis A, and Li KY (2002) Effect of several Chinese natural health products of human cytochrome P450 metabolism. J Pharm Pharm Sci 5: 185-189.
22. Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, and Sawada Y (2006) Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 34:577-582.
23. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, and Hall SD (2004) The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 75:89-100.
24. Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, and Zinny MA (2006) Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther 79:125-133.
25. Guengerich FP, Kim DH, and Iwasaki M (1991) Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168-179.
26. Guo B, Fan XR, Fang ZZ, Cao YF, Hu CM, Yang J, Zhang YY, He RR, Zhu X, and Yu ZW, et al. (2013) Deglycosylation of liquiritin strongly enhances its inhibitory potential towards UDP-glucuronosyltransferase (UGT) isoforms. Phytother Res 27:1232-1236.
27. Guo LQ, Taniguchi M, Chen QY, Baba K, and Yamazoe Y (2001) Inhibitory potential of herbal medicines on human cytochrome P450-mediated oxidation: properties of umbelliferous or citrus crude drugs and their relative prescriptions. Jpn J Pharmacol 85:399-408.
28. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, and Cheboyina S (2006) Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 46:201-213.
29. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, and Shah A (2004) In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 76:428-440.
30. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, and Ang CYW (2002) Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 72:276-287.
31. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, and Shah A (2005) In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 77:415-426.
32. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, and Battu SK (2008) Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 52:755-763.
33. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, and Gorski JC (2003) The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 74:525-535.
34. Ho BE, Shen DD, McCune JS, Bui T, Risler L, Yang Z, and Ho RJ (2010) Effects of garlic on cytochromes P450 2C9-and 3A4-mediated drug metabolism in human hepatocytes. Sci Pharm 78:473-481.
35. Hsiu SL, Hou YC, Wang YH, Tsao CW, Su SF, and Chao PD (2002) Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci 72:227-235.
36. Hu Z, Yang X, Ho PCL, Chan SY, Heng PWS, Chan E, Duan W, Koh HL, and Zhou S (2005) Herb-drug interactions: a literature review. Drugs 65:1239-1282.
37. Ioannides C, editor (1996) Cytochrome P450: Metabolic and Toxicological Aspects, CRC Press, New York.
38. Jancová P, Anzenbacherová E, Papousková B, Lemr K, Luzná P, Veinlichová A, Anzenbacher P, and Simánek V (2007) Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab Dispos 35:2035-2039.
39. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, and McLachlan AJ (2004) Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 57:592-599.
40. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, and Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 66:338-345.
41. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, and Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287:337-344.
42. Kawaguchi-Suzuki M, Frye RF, Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, and Markowitz JS (2014) The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity. Drug Metab Dispos 42:1611-1616.
43. Kent UM, Aviram M, Rosenblat M, and Hollenberg PF (2002) The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab Dispos 30:709-715.
44. Köck K, Xie Y, Hawke RL, Oberlies NH, and Brouwer KL (2013) Interaction of silymarin flavonolignans with organic anion-transporting polypeptides. Drug Metab Dispos 41:958-965.
45. Korobkova EA (2015) Effect of natural polyphenols on CYP metabolism: implications for diseases. Chem Res Toxicol 28:1359-1390.
46. Lefebvre T, Foster BC, Drouin CE, Krantis A, Livesey JF, and Jordan SA (2004) In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci 7:265-273.
47. Li AP and Doshi U (2011) Higher throughput human hepatocyte assays for the evaluation of time-dependent inhibition of CYP3A4. Drug Metab Lett 5:183-191.
48. Li J, Gödecke T, Chen SN, Imai A, Lankin DC, Farnsworth NR, Pauli GF, van Breemen RB, and Nikolic D (2011) In vitro metabolic interactions between black cohosh (Cimicifuga racemosa) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4. Xenobiotica 41:1021-1030.
49. Liang W, Li W, Nikolic D, and van Breemen RB (2003) LC-MS/MS determination of the inhibition of human cytochrome P450 isozymes by a standardized Trifolium pratense (red clover) extract. 51st American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics; 2003 Jun 8-12; Montreal, QC, Canada. American Society for Mass Spectrometry, Santa Fe, NM.
50. Lin LZ, He XG, Lian LZ, King W, and Elliot J (1998) Liquid chromatographic electrospray mass spectrometric study of the phthalides of Angelica sinensis and chemical changes of Z-ligustilide. J Chromatogr A 810:71-79.
51. Lindstrom A, Ooyen C, Lynch ME, and Blumenthal M (2013) Herb supplement sales increase 5.5% in 2012. HerbalGram 99:60-65.
52. Lindstrom A, Ooyen C, Lynch ME, Blumenthal M, and Kawa K (2014) Sales of herbal dietary supplements increase by 7.9% in 2013, marking a decade of rising sales: turmeric supplements climb to top ranking in natural channel. HerbalGram 103:52-56.
53. Maliakal PP and Wanwimolruk S (2001) Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol 53:1323-1329.
54. Mao J, Johnson TR, Shen Z, and Yamazaki S (2013) Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos 41:343-352.
55. Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, and Hall SD (2011) Prediction of CYP3Amediated drug-drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos 39:591-602.
56. Markowitz JS, Devane CL, Chavin KD, Taylor RM, Ruan Y, and Donovan JL (2003a) Effects of garlic (Allium sativum L) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 74:170-177.
57. Markowitz JS, Donovan JL, Devane CL, Taylor RM, Ruan Y, Wang JS, and Chavin KD (2003b) Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 74:536-542.
58. Mauro VF, Mauro LS, Kleshinski JF, Khuder SA, Wang Y, and Erhardt PW (2003) Impact of ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 10:247-251.
59. Modarai M, Rahte S, Kortenkamp A, and Heinrich M (2006) Screening herbal medicinal products for CYP P450 enzyme inhibition with the fast, robust Supersome assay (Abstract). Z Phytother 27:P25.
60. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL and Kliewer SA (2000) St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 97: 7500-7502.
61. Nabekura T, Yamaki T, Ueno K, and Kitagawa S (2008) Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochem Biophys Res Commun 369:363-368.
62. Netsch MI, Gutmann H, Schmidlin CB, Aydogan C, and Drewe J (2006) Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med 72:514-520.
63. Nowack R (2008) Review article: cytochrome P450 enzyme, and transport protein mediated herbdrug interactions in renal transplant patients: grapefruit juice, St John's Wort-and beyond! Nephrology (Carlton) 13:337-347.
64. Ohnishi N, Kusuhara M, Yoshioka M, Kuroda K, Soga A, Nishikawa F, Koishi T, Nakagawa M, Hori S, and Matsumoto T, et al. (2003) Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol Pharm Bull 26:1315-1320.
65. Ortiz de Montellano PR, editor (1995) Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd ed, Plenum Press, New York.
66. Paolini M, Barillari J, Broccoli M, Pozzetti L, Perocco P, and Cantelli-Forti G (1999) Effect of liquorice and glycyrrhizin on rat liver carcinogen metabolizing enzymes. Cancer Lett 145:35-42.
67. Parkinson A (1996) Biotransformation of xenobiotics, in Casarett & Doull's Toxicology: The Basic Science of Poisons (Klaassen CD editor) pp 113-186, McGraw-Hill Health Professions Division, New York.
68. Patel J, Buddha B, Dey S, Pal D, and Mitra AK (2004) In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 11:262-277.
69. Patten CJ, Thomas PE, Guy RL, Lee M, Gonzalez FJ, Guengerich FP, and Yang CS (1993) Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol 6:511-518.
70. Piersen CE, Booth NL, Sun Y, Liang W, Burdette JE, van Breemen RB, Geller SE, Gu C, Banuvar S, and Shulman LP, et al. (2004) Chemical and biological characterization and clinical evaluation of botanical dietary supplements: a phase I red clover extract as a model. Curr Med Chem 11:1361-1374.
71. Roberts DW, Doerge DR, Churchwell MI, Gamboa da Costa G, Marques MM, and Tolleson WH (2004) Inhibition of extrahepatic human cytochromes P450 1A1 and 1B1 by metabolism of isoflavones found in Trifolium pratense (red clover). J Agric Food Chem 52:6623-6632.
72. Shen DD, Kunze KL, and Thummel KE (1997) Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27:99-127.
73. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
74. Sridar C, Goosen TC, Kent UM, Williams JA, and Hollenberg PF (2004) Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 32:587-594.
75. Stout SM and Cimino NM (2014) Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 46:86-95.
76. Strandell J, Neil A, and Carlin G (2004) An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 11:98-104.
77. Strobl GR, von Kruedener S, Stöckigt J, Guengerich FP, and Wolff T (1993) Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem 36:1136-1145.
78. Sutter TR, Tang YM, Hayes CL, Wo YY, Jabs EW, Li X, Yin H, Cody CW, and Greenlee WF (1994) Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 269:13092-13099.
79. Tang JC, Zhang JN, Wu YT, and Li ZX (2006) Effect of the water extract and ethanol extract from traditional Chinese medicines Angelica sinensis (Oliv.) Diels, Ligusticum chuanxiong Hort. and Rheum palmatum L. on rat liver cytochrome P450 activity. Phytother Res 20:1046-1051.
80. Testa B and Krämer SD (2008) The biochemistry of drug metabolism-an introduction: part 4. reactions of conjugation and their enzymes. Chem Biodivers 5:2171-2336.
81. Tirona RG and Bailey DG (2006) Herbal product-drug interactions mediated by induction. Br J Clin Pharmacol 61:677-681.
82. Tsai HH, Lin HW, Simon Pickard A, Tsai HY, and Mahady GB (2012) Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. Int J Clin Pract 66:1056-1078.
83. Tsukamoto S, Aburatani M, and Ohta T (2005) Isolation of CYP3A4 inhibitors from the black cohosh (Cimicifuga racemosa). eCAM 2:223-226.
84. Uesawa Y and Mohri K (2006) Effects of cranberry juice on nifedipine pharmacokinetics in rats. J Pharm Pharmacol 58:1067-1072.
85. van Breemen RB (2015) Development of safe and effective botanical dietary supplements. J Med Chem DOI: [published ahead of print].
86. VandenBrink BM, Foti RS, Rock DA, Wienkers LC, and Wahlstrom JL (2012) Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos 40:47-53.
87. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, and Strom SC (2000) Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 28:1270-1273.
88. Wang Z, Gorski JC, Hamman MA, Huang S-M, Lesko LJ, and Hall SD (2001) The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70:317-326.
89. Wentworth JM, Agostini M, Love J, Schwabe JW, and Chatterjee VKK (2000) St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 166:R11-R16.
90. Whitten DL, Myers SP, Hawrelak JA, and Wohlmuth H (2006) The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 62:512-526.
91. Xu L, Chen Y, Pan Y, Skiles GL, and Shou M (2009) Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metab Dispos 37:2330-2339.
92. Yale SH and Glurich I (2005) Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 11:433-439.
93. Yuan Y, Qiu X, Nikolić D, Chen SN, Huang K, Li G, Pauli GF, and van Breemen RB (2014) Inhibition of human cytochrome P450 enzymes by hops (Humulus lupulus) and hop prenylphenols. Eur J Pharm Sci 53:55-61.
94. Zhao P (2008) The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo. Expert Opin Drug Metab Toxicol 4:151-164.
95. Zhou S, Lim LY, and Chowbay B (2004) Herbal modulation of P-glycoprotein. Drug Metab Rev 36:57-104.
96. Zou L, Harkey MR, and Henderson GL (2002) Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71:1579-1589.
97. Zuber R, Modrianský M, Dvorák Z, Rohovský P, Ulrichová J, Simánek V, and Anzenbacher P (2002) Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 16:632-638.